Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia

2007 ◽  
pp. 495-501
Author(s):  
Jean-Philippe Charrier ◽  
Carole Tournel ◽  
Sandrine Michel ◽  
Pascal Dalbon ◽  
Michel Jolivet
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Two Dimensional ◽  
Prostate Hyperplasia ◽  
Two Dimensional Electrophoresis ◽  
Benign Prostate ◽  
Dimensional Electrophoresis

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

scholarly journals Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer

2004 ◽  
Vol 50 (12) ◽  
pp. 2292-2301 ◽  
Author(s):  
Klaus Jung ◽  
Janett Reiche ◽  
Axel Boehme ◽  
Carsten Stephan ◽  
Stephan A Loening ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Accuracy ◽  
Prostate Specific Antigen ◽  
Magnetic Beads ◽  
Specific Antigen ◽  
Cancer Diagnostics ◽  
Two Dimensional ◽  
Two Dimensional Gel Electrophoresis ◽  
Two Dimensional Electrophoresis ◽  
Dimensional Electrophoresis

Abstract Background: The aim of this study was to develop a method to separate and quantify subforms of free prostate-specific antigen (fPSA) in serum by two-dimensional electrophoresis and to assess the diagnostic accuracy of these subforms for prostate cancer (PCa) diagnosis in comparison with total PSA (tPSA) and the ratio of fPSA to tPSA (%fPSA). Methods: Sera from 50 patients with and without PCa, respectively, were studied. PSA was isolated by immunoadsorption on streptavidin-coated magnetic beads with biotinylated anti-PSA antibodies and separated by two-dimensional electrophoresis. After semidry blotting, the intensities of the fPSA spots were quantified by chemiluminescence using an imager analyzer. Results: The method detected subforms to a concentration of 0.1 μg/L fPSA with an imprecision (CV) <16%. We detected 15 immunoreactive fPSA spots of different intensities. Spots F2 and F3 were present in all samples. F2 was lower in samples from non-PCa patients (median, 23%) than in samples from PCa patients (49%), whereas F3 behaved inversely (non-PCa, 73%; PCa, 45%). Ratios of F2 to F3 and F2/F3 to %fPSA, respectively, showed improved diagnostic accuracy compared with tPSA and %fPSA. Better differentiation by F2/F3 or by F2/F3 to %fPSA was particularly evident in patients with %fPSA values >15%. There were no associations between the PCa grading scale and fPSA subforms. Conclusions: fPSA subforms separated by two-dimensional electrophoresis may improve both sensitivity and specificity in prostate cancer diagnostics compared with tPSA and %fPSA. The development of a practicable assay based on the immunologic properties of these different fPSA subforms seems to be promising.

scholarly journals Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness

Tumor Biology ◽  
2019 ◽  
Vol 41 (3) ◽  
pp. 101042831982722 ◽  
Author(s):  
Robert Lang ◽  
Vinzent Rolny ◽  
Andreas Leinenbach ◽  
Johann Karl ◽  
Magdalena Swiatek-de Lange ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostate Hyperplasia ◽  
Aggressive Prostate Cancer ◽  
Total Prostate Specific Antigen ◽  
Benign Prostate ◽  
Core Fucosylation

Prostate cancer represents a major cause of cancer death in men worldwide. Novel non-invasive methods are still required for differentiation of non-aggressive from aggressive tumors. Recently, changes in prostate-specific antigen glycosylation pattern, such as core-fucosylation, have been described in prostate cancer. The objective of this study was to evaluate whether the core-fucosylation determinant of serum prostate-specific antigen may serve as refined marker for differentiation between benign prostate hyperplasia and prostate cancer or identification of aggressive prostate cancer. A previously developed liquid chromatography–mass spectrometry/mass spectrometry–based strategy was used for multiplex analysis of core-fucosylated prostate-specific antigen (fuc-PSA) and total prostate-specific antigen levels in sera from 50 benign prostate hyperplasia and 100 prostate cancer patients of different aggressiveness (Gleason scores, 5–10) covering the critical gray area (2–10 ng/mL). For identification of aggressive prostate cancer, the ratio of fuc-PSA to total prostate-specific antigen (%-fuc-PSA) yielded a 5%–8% increase in the area under the curve (0.60) compared to the currently used total prostate-specific antigen (area under the curve = 0.52) and %-free prostate-specific antigen (area under the curve = 0.55) tests. However, our data showed that aggressive prostate cancer (Gleason score > 6) and non-aggressive prostate cancer (Gleason score ≤ 6) could not significantly (p-value = 0.08) be differentiated by usage of %-fuc-PSA. In addition, both non-standardized fuc-PSA and standardized %-fuc-PSA had no diagnostic value for differentiation of benign prostate hyperplasia from prostate cancer. The %-fuc-PSA serum levels could not improve the differentiation of non-aggressive and aggressive prostate cancer compared to conventional diagnostic prostate cancer markers. Still, it is unclear whether these limitations come from the biomarker, the used patient cohort, or the imprecision of the applied method itself. Therefore, %-fuc-PSA should be further investigated, especially by more precise methods whether it could be clinically used in prostate cancer diagnosis.

scholarly journals The prediction of Prostate Cancer Based on Normal Digital Rectal Examination and Normal Prostate Specific Antigen in Clinical Benign Prostate Hyperplasia

2018 ◽  
Vol 5 (4) ◽  
pp. 3760-3763
Author(s):  
Zuhirman Zamzami
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Ethical Review ◽  
Normal Prostate ◽  
Prostate Hyperplasia ◽  
Prostate Enlargement ◽  
Benign Prostate

Purpose: To evaluate the prediction of prostate cancer based on normal digital examination (DRE) and normal prostate specific antigen (PSA) in clinical Benign Prostate Hyperplasia. Materials and Methods: We reviewed medical records of prostate cancer in prostate enlargement patients with urinary retension underwent transurethral resection of the prostate  (TURP) based on  normal DRE, and normal PSA in Arifin Achmad Regional General Hospital, Pekanbaru, Riau Province, Indonesia in January 2010 – Desember 2016. Statistical analysis of univariate was used. Approval on the study was obtained from the Ethical Review Board for Medicine and Health Research, Medical Faculty, University of Riau. Results: There were 644 prostate enlargement patients with urinary retension underwent TURP) in this study in which mostly (51%) in 60-69 year age group,  Most (69.7%) DRE were normal and PSA levels of ≤ 4 ng/ml  were in 122 (19%) patients. There were 19 (18.5%) prostate cancer in patients with normal DRE and PSA. Conclusion: We found there were 19 (18.5%) prostate cancers in prostate enlargement patients with normal DRE and PSA findings as the prediction.

Sign in / Sign up

Export Citation Format

Share Document